Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Voyager Therapeut (VYGR)

Voyager Therapeut (VYGR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 111,532
  • Shares Outstanding, K 37,936
  • Annual Sales, $ 171,130 K
  • Annual Income, $ 36,740 K
  • 60-Month Beta 0.97
  • Price/Sales 0.65
  • Price/Cash Flow 3.07
  • Price/Book 1.14
Trade VYGR with:

Options Overview Details

View History
  • Implied Volatility 106.88%
  • Historical Volatility 54.63%
  • IV Percentile 32%
  • IV Rank 25.56%
  • IV High 256.48% on 02/26/21
  • IV Low 55.52% on 07/21/21
  • Put/Call Vol Ratio 0.06
  • Today's Volume 100
  • Volume Avg (30-Day) 33
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 908
  • Open Int (30-Day) 1,236

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.75
  • Number of Estimates 4
  • High Estimate -0.64
  • Low Estimate -0.86
  • Prior Year 2.27
  • Growth Rate Est. (year over year) -133.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.90 +1.20%
on 09/23/21
3.63 -19.01%
on 09/02/21
-0.25 (-7.84%)
since 08/24/21
3-Month
2.82 +4.26%
on 08/20/21
4.58 -35.81%
on 06/25/21
-1.50 (-33.78%)
since 06/24/21
52-Week
2.82 +4.26%
on 08/20/21
12.65 -76.76%
on 10/16/20
-8.64 (-74.61%)
since 09/24/20

Most Recent Stories

More News
5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal

The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others

SRPT : 90.57 (+0.03%)
ABBV : 107.07 (-0.27%)
QURE : 33.77 (-5.99%)
VYGR : 2.94 (+0.34%)
RGNX : 42.32 (-2.67%)
SLDB : 2.67 (-9.80%)
MGTX : 13.37 (-1.55%)
Spinal Muscular Atrophy Treatment Market Key Players, Industry Overview and Forecasts to 2028

Research Nester published a report titled  which delivers a detailed overview of the Spinal muscular atrophy drug market in terms of market segmentation by treatment, by route of administration, by disease...

NOVN : 8.14 (-3.78%)
PFE : 43.94 (-0.57%)
BIIB : 291.71 (-0.51%)
PTCT : 39.29 (-0.48%)
VYGR : 2.94 (+0.34%)
CYTK : 33.13 (-1.43%)
IONS : 36.20 (-2.69%)
REGN : 638.90 (-1.18%)
Voyager Therapeutics to Participate in Upcoming Investor Conferences

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation platform technologies, today announced that it will participate in the following...

VYGR : 2.94 (+0.34%)
Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -6.67% and -66.41%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

VYGR : 2.94 (+0.34%)
Voyager Therapeutics: Q2 Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Voyager Therapeutics Inc. (VYGR) on Monday reported a loss of $30.1 million in its second quarter.

VYGR : 2.94 (+0.34%)
Voyager Therapeutics Transforms Pipeline and Increases Investment in Next-Generation TRACER(TM) AAV Capsid and Vectorized Antibody Platform Technologies

Proprietary AAV capsids to power second-generation efforts in Huntington's disease and ALS, pre-clinical programs in spinal muscular atrophy and diseases linked to GBA1 mutations

VYGR : 2.94 (+0.34%)
Analysts Estimate Voyager Therapeutics (VYGR) to Report a Decline in Earnings: What to Look Out for

Voyager Therapeutics (VYGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VYGR : 2.94 (+0.34%)
Aerovate Therapeutics Appoints Allison Dorval To Its Board of Directors

Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today...

VYGR : 2.94 (+0.34%)
AVTE : 16.69 (+3.28%)
Voyager Therapeutics Announces Strategic Shift and Leadership Transitions

Company focusing on rapidly moving VY-HTT01 into clinical development for Huntington's disease and maximizing opportunities created by TRACER gene therapy technology platform and next-generation targeted...

VYGR : 2.94 (+0.34%)
Voyager Therapeutics Presents New Preclinical Data Showing Reduction of Pathological Tau with Vectorized Anti-Tau Antibody

Findings to be presented at the 24 Annual Meeting of the American Society of Gene and Cell Therapy

VYGR : 2.94 (+0.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs...

See More

Key Turning Points

3rd Resistance Point 3.08
2nd Resistance Point 3.04
1st Resistance Point 2.99
Last Price 2.94
1st Support Level 2.90
2nd Support Level 2.86
3rd Support Level 2.81

See More

52-Week High 12.65
Fibonacci 61.8% 8.89
Fibonacci 50% 7.73
Fibonacci 38.2% 6.58
Last Price 2.94
52-Week Low 2.82

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar